The FDA keeps a public table of every stand-in it has accepted to approve a drug, and the Alzheimer's plaque from part one still has a row; aging has none. Part two of three: what each row has that every aging clock lacks, read from the table's last column.
A $499 kit in the mail reports a pace of aging, and nothing yet says whether that number stands in for the years ahead. Part three of three: I map the system that keeps drugs for aging from approval, find the one missing arrow, made of evidence, and set out the analysis that would draw it.
In 2021 the FDA approved an Alzheimer's drug for clearing plaque from the brain, a stand-in for slower memory loss, though the patient who lost the most plaque got three points worse. Part one of three: the agency's own statistical review, read section by section, and what to ask before a parent starts a drug on a clean scan.